Saturday, April 10, 2021 10:45:23 AM
Topic: “VASCEPA: Multi-Factorial MOA for Benefits Beyond Cardiovascular Protection”
Recently Dr. Deepak Bhatt co-authored a paper titled “Beyond cardiovascular medicine: potential future uses of icosapent ethyl” in which the authors detail “data supporting the use of icosapent ethyl in patients similar to those enrolled in REDUCE-IT”, for multiple clinical indications.
Unfortunately, most prescribers of drug medications today are still unaware of VASCEPA® brand icosapent ethyl, its indicated use(s), or its supporting clinical trials, (MARINE, ANCHOR, REDUCE-IT, EVAPORATE, etc.).
That’s why I put together this simple visualization (only 9 slides), in PowerPoint or PDF format, as a “handout” for your doctor. Each slide is a simple representation of the multi-factorial benefits of VASCEPA as a cardiovascular protector and beyond.
The handout will be available in CaptBeer’s Google Drive on Sunday.
Pass it on…
Recent AMRN News
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
